Abliva
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
ABLI | ST
Overview
Corporate Details
- ISIN(s):
- SE0002575340
- LEI:
- 5493005YV22OTMUHZ183
- Country:
- Sweden
- Address:
- Medicon Village, 223 81 Lund
- Website:
- https://abliva.com
- Sector:
- Manufacturing
Description
Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-03 13:10 |
Delisting of the shares of Abliva: last day of trading 17 March 2025
|
English | 64.3 KB | ||
| 2025-03-03 13:10 |
Avnotering av aktierna i Abliva: sista handelsdag 17 mars 2025
|
Swedish | 64.1 KB | ||
| 2025-02-26 08:30 |
Notice of Extraordinary General Meeting in Abliva AB (publ)
|
English | 74.8 KB | ||
| 2025-02-26 08:30 |
Kallelse till extra bolagsstämma i Abliva AB (publ)
|
Swedish | 75.2 KB | ||
| 2025-02-25 09:50 |
Abliva applies for delisting and will convene an extraordinary general meeting
|
English | 64.9 KB | ||
| 2025-02-25 09:50 |
Abliva ansöker om avnotering och kommer att kalla till extra bolagsstämma
|
Swedish | 65.1 KB | ||
| 2025-02-21 14:41 | Swedish | 9.6 KB | |||
| 2025-02-21 08:30 | Swedish | 2.6 MB | |||
| 2025-02-21 08:30 | English | 2.6 MB | |||
| 2025-02-12 11:37 | Swedish | 9.5 KB | |||
| 2025-02-11 15:52 | Swedish | 9.7 KB | |||
| 2024-12-15 20:00 |
Uttalande från Ablivas styrelse med anledning av Pharmings kontanta offentliga …
|
Swedish | 83.3 KB | ||
| 2024-12-15 20:00 |
Statement by the Board of Directors of Abliva regarding the public cash offer f…
|
English | 80.9 KB | ||
| 2024-11-29 18:00 | Swedish | 2.9 MB | |||
| 2024-11-29 18:00 | English | 2.9 MB |
Automate Your Workflow. Get a real-time feed of all Abliva filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abliva
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abliva via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-07 | David Bejker | Other | Sell | 269,005 | 121,052.25 SEK |
| 2024-05-31 | Catharina Janzon Johansson | Other | Other | 2,000,000 | 60,000.00 SEK |
| 2024-05-28 | David Laskow-Pooley | Other | Other | 1,000,000 | 30,000.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 54,128 | 11,664.58 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 38,000 | 8,151.00 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 36,064 | 7,807.86 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 15,091 | 3,267.20 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,901 | 2,588.47 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,270 | 2,479.40 SEK |
| 2023-07-13 | David Laskow-Pooley | Other | Buy | 11,275 | 2,474.86 SEK |
Peer Companies
